About: Immune Parameters and COVID-19 Infection – Associations With Clinical Severity and Disease Prognosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immune Parameters and COVID-19 Infection – Associations With Clinical Severity and Disease Prognosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immune Parameters and COVID-19 Infection – Associations With Clinical Severity and Disease Prognosis
Creator	Wang, Penghua Sharp, Robert Banovcin, Peter Bobcakova, Anna Brndiarova, Miroslava Jesenak, Milos Ostro, Robert Rennerova, Zuzana Urbancikova, Ingrid Vojtkova, Jarmila Seveau, Stephanie
Source	Medline; PMC
abstract	Severe acute respiratory syndrome caused by a novel 2019 coronavirus (SARS-CoV2) represents one of the most studied infectious diseases of today. The number of scientific reports and publications increases exponentially day by day. While the majority of infected subjects are asymptomatic or show mild symptoms, there is an important proportion of patients who requires hospitalization and, sometimes, intensive care. Immune response to novel coronavirus is complex, involves both innate and adaptive immunity, and is biphasic. Significant differences were observed when comparing severe and non-severe patients. Analysis of the reported results from clinical trials clearly show an involvement of specific cellular immunity (predominantly leucopenia, decreased counts of CD3(+), CD4(+), and CD8(+) T lymphocytes, changes of T cell compartment) and the so-called cytokine storm, which is associated with worsening of symptoms and the promotion of lung damage. An interesting finding regarding eosinopenia that can have both diagnostic and prognostic value is reported by some authors. Examination of selected immune parameters could help to identify severe patients with the risk of unfavorable course of the disease, predict the prognosis and recognize improvement in the clinical status. Moreover, detailed analysis of the immune changes could help to select novel prospective therapeutic strategies.
has issue date	2020-06-30(xsd:dateTime)
bibo:doi	10.3389/fcimb.2020.00364
bibo:pmid	32695683
has license	cc-by
sha1sum (hex)	37f24b452ca6885ae0bb86d4a065e3d4931d9c5f
schema:url	https://doi.org/10.3389/fcimb.2020.00364
resource representing a document's title	Immune Parameters and COVID-19 Infection – Associations With Clinical Severity and Disease Prognosis
has PubMed Central identifier	PMC7338601
has PubMed identifier	32695683
schema:publication	Front Cell Infect Microbiol
resource representing a document's body	covid:37f24b452ca6885ae0bb86d4a065e3d4931d9c5f#body_text
is schema:about of	named entity 'asymptomatic' named entity 'disease' named entity 'patients' named entity 'PROSPECTIVE' named entity 'INCREASES' named entity 'IMPROVEMENT' named entity 'PROPORTION' named entity 'IMMUNE RESPONSE' named entity 'SUBJECTS' named entity 'BIPHASIC' named entity 'COURSE' named entity 'REPORTED' named entity 'INFECTIOUS DISEASES' named entity 'selected' named entity 'immunity' named entity 'strategies' named entity 'represents' named entity 'detailed' named entity 'coronavirus' named entity 'identify' named entity 'complex' named entity 'recognize' named entity 'specific' named entity 'comparing' named entity 'mild' named entity 'severe' named entity 'cytokine storm' named entity 'Severe acute respiratory syndrome' named entity 'biphasic' named entity 'majority' named entity 'innate' named entity 'leucopenia' named entity 'caused' named entity 'scientific reports' named entity 'CD4' named entity 'Immune response' named entity 'SARS-CoV2' named entity 'lung' named entity 'biphasic' named entity 'increases exponentially' named entity 'cellular immunity' named entity 'IL-1' named entity 'cytokines' named entity 'HLA-DR' named entity 'antiviral drugs' named entity 'inflammatory response' named entity 'eosinopenia' named entity 'lung' named entity 'eosinopenia' named entity 'CD8' named entity 'apoptosis' named entity 'polysaccharides' named entity 'bilirubin' named entity 'coronaviruses' named entity 'COVID' named entity 'CD8 +' named entity 'cytokines' named entity 'Zinc' named entity 'vitamin' named entity 'HLA-DR' named entity 'inflammation' named entity 'gene expression' named entity 'IgM' named entity 'MAP2K7' named entity 'cytokine storm' named entity 'CD4' named entity 'Th17' named entity 'pneumonia' named entity 'antigen presenting cells' named entity 'Eosinopenia' named entity 'programmed cell death 1'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software